Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer

British Journal of Cancer

Volumn 90, Issue 7, 2004, Pages 1318-1322

  Barlow, C ^a   Nystrom, M ^a   Oesterling, C ^a   Fennell, D ^a   Ismay, J ^a   Gallagher, C ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Carboplatin; Gemcitabine; Ovarian cancer; Paclitaxel; Peripheral blood progenitor cell support

Indexed keywords

CARBOPLATIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD TOXICITY; BLOOD TRANSFUSION; BLOOD VOLUME; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; INFLAMMATION; INFUSION; LIVER TOXICITY; MALAISE; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHLEBOTOMY; PRIORITY JOURNAL; SIDE EFFECT; TEMPERATURE; THROMBOCYTOPENIA; TIME; TOXICITY; TRANSAMINITIS;

ADOLESCENT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; TRANSPLANTATION, AUTOLOGOUS;

EID: 2342475204     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601697     Document Type: Article

References (27)

1. Aapro MS, Martin C, Hatty S (1998) Gemcitabine - a safety review. Anti Cancer Drugs 9: 191-201
2. Allerheiligen S, Johnson R, Hatcher B, Freeman K, Tarassoff P, Voi M, Dorr A (1994) Gemcitabine pharmacokinetics are influenced by gender, body surface area (BSA) and duration of infusion. Proc Am Soc Clin Oncol 13: 136
3. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ (1996) Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2: 521-530
4. Coeman DC, Verbeken EK, Nackaerts KL, Demedts MG, Vansteenkiste JF (2000) A fatal case of cholestatic liver failure probably related to gemcitabine. Ann Oncol 11: 1503
5. Dobbie M, Hofer S, Oberholzer M, Herrmann R (1998) Veno-occlusive disease of the liver induced by gemcitabine. Ann Oncol 9: 681
6. Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK (1997) Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 15: 310-316
7. Friedlander M, Millward MJ, Bell D, Bugat R, Harnett P, Moreno JA, Campbell L, Varette C, Ripoche V, Kayitalire L (1998) A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer [comment]. Ann Oncol 9: 1343-1345
8. Geertsen P, Hansen M, Stroyer I, Hansen S (1999) Combination chemotherapy with platinum, paclitaxel, and gemcitabine in patients with relapsed ovarian carcinoma. Proc Am Soc Clin Oncol 18: 361a (Abstract 1395)
9. Hansen SW (2002) Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin Oncol 29: 17-19
10. Hansen SW, Andersen H, Boman K, Hansen M, Havsteen H, Rosenberg P, Sorensen P, Vergote I (1999a) Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proc Am Soc Clin Oncol 18: 357a (Abstract 1379)
11. Hansen SW, Tuxen MK, Sessa C (1999b) Gemcitabine in the treatment of ovarian cancer. Ann Oncol 10(Suppl 1): S51-S53
12. Harper P (1999) A randomised comparison of paclitaxel (T) and carboplatin (J) versus a control arm of single agent carboplatin (J) or CAP (cyclophosphamide, doxorubicin and cisplatin): 2075 patients randomised into the 3rd International Collaborative Ovarian Neoplasm Study (ICON3). Proc Am Soc Clin Oncol 18: 356a (Abstract 1375)
13. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117
14. Ledermann JA, Herd R, Maraninchi D, Viens P, Buclon M, Philip T, Cure H, Lotz JP, Chauvin F, Ferrante P, Rosti G (2001) High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT) [comment]. Ann Oncol 12: 693-699
15. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP (1994) Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530-1533
16. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [comment]. N Engl J Med 334: 1-6
17. Pettengell R, Woll PJ, Carmichael J (1999) Phase I study of multicyclic dose-intensive carboplatin/paclitaxel supported by haemopoietic progenitor cell reinfusion in whole blood. Proc Am Soc Clin Oncol 18:43a (Abstract 163)
18. Pettengell R, Woll PJ, Thatcher N, Dexter TM, Testa NG (1995) Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 13: 148-156
19. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results [comment]. J Natl Cancer Inst 92: 699-708
20. Plunkett W, Huang P, Searcy CE, Gandhi V (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23: 3-15
21. Poole CJ, Jordan SD, Higgins HB, Archer VR, Pemberton GE (2001) A phase I intra and interpatient dose ranging trial of gemcitabine, carboplatin and paclitaxel (GCP) in combination in previously untreated patients with epithelial ovarian cancer, primary peritoneal malignancy, ovarian carcinosarcoma and fallopian tube carcinoma. In Proc Am Soc Clin Oncol 20: 220a (Abstract 878)
22. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC (1996) Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63: 89-93
23. Underhill CR, Parnis FX, Highley MS, Ahern J, Harper PG, Hansen H, Lund B, Dombernowsky P, Hirsch F, Hansen M, Carmichael J, Williams C (2001) Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Anti Cancer Drugs 12: 647-652
24. van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ (1999) Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 80: 981-990
25. Voak D, Finney RD, Forman K, Kelsey P, Mitchell R (1993) Guidelines for autologous transfusion. I. Pre-operative autologous donation. Transfus Med 3: 307-316
26. Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N (1995) Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 13: 652-659
27. Woll PJ, Thatcher N, Lomax L, Hodgetts J, Lee SM, Burt PA, Stout R, Simms T, Davies R, Pettengell R (2001) Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients. J Clin Oncol 19: 712-719